About RS BioTherapeutics
RS BioTherapeutics is a private company based in Cumberland, Maryland, incorporated in 2021 in Delaware. It has reported $1,910,021 raised in four offerings on Form D since June 2022.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 26, 2024 | Oct 9, 2024 | $20,000of $2.0M target | 1 | $20,000 | Equity, Simple Agreement for Future EquityRule 506(b) | Form D ↗ |
| Oct 6, 2023 | Aug 10, 2023amended Oct 19, 2023 | $1,105,000of $5.0M target | 5 | $221K | Equity, Simple Agreement for Future EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Nov 16, 2022 | Mar 22, 2023 | $100,000of $10.0M target | 1 | $100K | EquityRule 506(b) | Form D ↗ |
| Jun 9, 2022 | Jun 21, 2022 | $685,021of $4.0M target | 6 | $114K | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $1,910,021 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on RS BioTherapeutics's Form D filed Oct 9, 2024.
MG
Michael Guzman
Executive officer
HH
H. Hart
Executive officer
CR
Curtis Rhine
Chief Financial Officer
JM
Justin Molignoni
Executive officer and director
DF
David Freas
Director
Earlier filings also listed Dustin Freas (director, last listed Mar 2023).